Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Amortizatization of Intangibles (2021 - 2025)

Prime Medicine (PRME) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 17.89% year-over-year to $2.6 million, compared with a TTM value of $9.7 million through Dec 2025, down 21.51%, and an annual FY2025 reading of $9.7 million, down 21.51% over the prior year.
  • Amortizatization of Intangibles was $2.6 million for Q4 2025 at Prime Medicine, up from $2.3 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $5.7 million in Q2 2023 and bottomed at -$715000.0 in Q4 2021.
  • Average Amortizatization of Intangibles over 5 years is $2.6 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Amortizatization of Intangibles skyrocketed 491.33% in 2022, then tumbled 65.58% in 2023.
  • Year by year, Amortizatization of Intangibles stood at -$715000.0 in 2021, then surged by 491.33% to $2.8 million in 2022, then rose by 19.66% to $3.3 million in 2023, then tumbled by 34.05% to $2.2 million in 2024, then rose by 17.89% to $2.6 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for PRME at $2.6 million in Q4 2025, $2.3 million in Q3 2025, and $2.3 million in Q2 2025.